Q4 2018: Growth in fourth quarter closes the year
Significant events in the fourth quarter• Fourth-quarter net sales rose to MSEK 163, up 36%, or MSEK 43 compared with the year-on-year period, due to continued recovery from a customer-specific destocking programme• First commercial order after the introduction of Probi’s product to improve bone health in postmenopausal women – Probi® Osteo• Promising initial results from clinical trials to evaluate the effects of Probi’s strains on physical performance and acute stress• Tom Rönnlund appointed new CEO as of January 1, 2019 and Henrik Lundkvist new CFO as of January 7, 2019• Board